CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans cells (Memorial Sloan Kettering Cancer Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans cells (Memorial Sloan Kettering Cancer Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionWilms' Tumour 1 modulators
TargetsWilms' Tumour 1
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A